These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18949462)

  • 1. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.
    Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Saunder T; Young K; Smith CL; Welch J; Woodward M; Wesnes KA; Savage G; Rowe CC
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):79-91. PubMed ID: 18949462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.
    Ellis JR; Villemagne VL; Nathan PJ; Mulligan RS; Gong SJ; Chan JG; Sachinidis J; O'Keefe GJ; Pathmaraj K; Wesnes KA; Savage G; Rowe CC
    Neurobiol Learn Mem; 2008 Sep; 90(2):404-12. PubMed ID: 18620875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380.
    Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Ellis KA; Tochon-Danguy HJ; Chan JG; O'keefe GJ; Bradley J; Savage G; Rowe CC
    Synapse; 2009 Sep; 63(9):752-63. PubMed ID: 19484724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Sabri O; Meyer PM; Gräf S; Hesse S; Wilke S; Becker GA; Rullmann M; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Tiepolt S; Fischer S; Deuther-Conrad W; Hegerl U; Barthel H; Schönknecht P; Brust P
    Brain; 2018 Jun; 141(6):1840-1854. PubMed ID: 29672680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
    Nikiforuk A; Potasiewicz A; Kos T; Popik P
    Behav Brain Res; 2016 Oct; 313():214-218. PubMed ID: 27435422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys.
    Valette H; Bottlaender M; Dollé F; Coulon C; Ottaviani M; Syrota A
    Synapse; 2005 Jun; 56(4):217-21. PubMed ID: 15803498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.
    Kendziorra K; Wolf H; Meyer PM; Barthel H; Hesse S; Becker GA; Luthardt J; Schildan A; Patt M; Sorger D; Seese A; Gertz HJ; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):515-25. PubMed ID: 21069319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
    Lilienfeld S
    CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.
    Kadir A; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2006 Nov; 188(4):509-20. PubMed ID: 16832659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET.
    Mitkovski S; Villemagne VL; Novakovic KE; O'Keefe G; Tochon-Danguy H; Mulligan RS; Dickinson KL; Saunder T; Gregoire MC; Bottlaender M; Dolle F; Rowe CC
    Nucl Med Biol; 2005 Aug; 32(6):585-91. PubMed ID: 16026705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET.
    Gallezot JD; Bottlaender M; Grégoire MC; Roumenov D; Deverre JR; Coulon C; Ottaviani M; Dollé F; Syrota A; Valette H
    J Nucl Med; 2005 Feb; 46(2):240-7. PubMed ID: 15695782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment.
    Mitsis EM; Reech KM; Bois F; Tamagnan GD; Macavoy MG; Seibyl JP; Staley JK; van Dyck CH
    J Nucl Med; 2009 Sep; 50(9):1455-63. PubMed ID: 19690024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients.
    Keller C; Kadir A; Forsberg A; Porras O; Nordberg A
    J Alzheimers Dis; 2011; 24(1):109-23. PubMed ID: 21157026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects.
    Hahn B; Shrieves ME; Olmstead CK; Yuille MB; Chiappelli JJ; Pereira EFR; Albuquerque EX; Fawcett WP
    Psychopharmacology (Berl); 2020 Jan; 237(1):219-230. PubMed ID: 31686175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease.
    Schmaljohann J; Minnerop M; Karwath P; Gündisch D; Falkai P; Guhlke S; Wüllner U
    Appl Radiat Isot; 2004 Dec; 61(6):1235-40. PubMed ID: 15388115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study.
    Picard F; Bruel D; Servent D; Saba W; Fruchart-Gaillard C; Schöllhorn-Peyronneau MA; Roumenov D; Brodtkorb E; Zuberi S; Gambardella A; Steinborn B; Hufnagel A; Valette H; Bottlaender M
    Brain; 2006 Aug; 129(Pt 8):2047-60. PubMed ID: 16815873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.
    Takata K; Kitamura Y; Saeki M; Terada M; Kagitani S; Kitamura R; Fujikawa Y; Maelicke A; Tomimoto H; Taniguchi T; Shimohama S
    J Biol Chem; 2010 Dec; 285(51):40180-91. PubMed ID: 20947502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
    Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.